N-acetyl-L-leucine normalizes Transcription Factor EB activity by stereospecific bidirectional modulation in a HeLa cell model of Niemann-Pick disease type C
PLOS One · 17.07.2026 · 21 (7) · e0353834
DOI: 10.1371/journal.pone.0353834 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 17.07.2026. Verfasst von Lianne C Davis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Oxford, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Leucine, Niemann-Pick Disease, Type C. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Legacy Foundation, Fridolin Foundation, IntraBio Inc.
Abstract (Originalsprache)
Levacetylleucine (Aqneursa™), an acetylated derivative and pro-drug of L-leucine, is the only FDA-approved monotherapy for Niemann–Pick disease type C (NPC). Its acetyl group enables transport via monocarboxylate transporters, supporting blood–brain barrier penetration and efficient cellular uptake. Inside cells, levacetylleucine is metabolised by acylases, generating elevated levels of L-leucine that enhance mitochondrial bioenergetics and is thought to ameliorate lysosomal dysfunction indirectly. Here, we describe a direct effect of levacetylleucine on lysosomal regulation through modulation of TFEB, the master transcription factor for lysosomal and autophagy genes. Levacetylleucine rapidly alters TFEB translocation between the cytoplasm and the nucleus in a biphasic, homeostasis-restoring manner. In wild-type HeLa cells, levacetylleucine promotes TFEB activation and nuclear localisation. However, in NPC1 disease models, where we show that TFEB is over-activated and enriched in the nucleus due to lysosomal stress, levacetylleucine reduces nuclear TFEB and restores a more normal cytoplasmic-to-nuclear balance. These effects occur at clinically relevant concentrations associated with lysosomal storage reduction. The effects of the drug are stereospecific: while the L-enantiomer is active, the D-enantiomer and racemate show no effect, revealing the antagonistic properties of the D-enantiomer. This bidirectional normalisation of TFEB activity highlights a direct mechanism through which levacetylleucine modulates lysosomal and autophagic pathways in the HeLa cell model, giving mechanistic insight into its therapeutic potential in NPC, and also across diverse neurological and neurodevelopmental disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Oxford, Oxford, United Kingdom.
- VIB Center for Neuroscience Leuven & Department of Neurosciences, Laboratory for Membrane Trafficking, Leuven, Belgium.
- IntraBio Inc, Austin, United States of America.
- Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.
ORCID-Profile: Wim Annaert, Antony Galione
Förderung
- Legacy Foundation
- Fridolin Foundation
- IntraBio Inc
Zitieren
APA
Davis, L. C., Annaert, W., Braine, R., Churchill, G. C., Factor, M., Fields, T., Patterson, M., Platt, F., Shepherd, D., Strupp, M., & Galione, A. (2026). N-acetyl-L-leucine normalizes Transcription Factor EB activity by stereospecific bidirectional modulation in a HeLa cell model of Niemann-Pick disease type C. PLOS One, 21(7), e0353834. https://doi.org/10.1371/journal.pone.0353834
Vancouver
Davis LC, Annaert W, Braine R, Churchill GC, Factor M, Fields T, et al. N-acetyl-L-leucine normalizes Transcription Factor EB activity by stereospecific bidirectional modulation in a HeLa cell model of Niemann-Pick disease type C. PLOS One. 2026;21(7):e0353834. doi:10.1371/journal.pone.0353834
BibTeX
@article{Davis2026,
author = {Davis, Lianne C and Annaert, Wim and Braine, Rebecca and Churchill, Grant C and Factor, Mallory and Fields, Taylor and Patterson, Marc and Platt, Frances and Shepherd, Dawn and Strupp, Michael and Galione, Antony},
title = {N-acetyl-L-leucine normalizes Transcription Factor EB activity by stereospecific bidirectional modulation in a HeLa cell model of Niemann-Pick disease type C},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0353834},
doi = {10.1371/journal.pone.0353834}
}
EUVIMED